News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Post-Approval (World)
Study Claims Celgene (CELG) Drug Can Drive HIV Out Of Hiding 7/25/2014
CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In The Netherlands 7/21/2014
Shire Reports Results From Two Head-To-Head Studies Comparing Vyvanse® With Concerta® In ADHD Study 7/18/2014
Merck & Co., Inc. (MRK)'s Gardasil HPV Vaccine Doesn't Increase Blood Clot Risk 7/9/2014
Roche (RHHBY) Finds "Serious Flaws" In Recent Study Doubting Tamiflu's Effectiveness 7/1/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
H. Lundbeck A/S (LUN.CO) Release: New Study Results Demonstrate Brintellix® (Vortioxetine) Is Efficacious In Asian Patients Suffering From Depression 6/26/2014
A 4-Week Hepatitis C Cure? Bristol-Myers Squibb Company (BMY) To Test Drugs With Gilead Sciences, Inc. (GILD)'s Sovaldi 6/23/2014
H. Lundbeck A/S (LUN.CO) Release: Brintellix® Demonstrated A Statistically Significantly Superior Improvement Compared To Escitalopram In Improving Sexual Functioning In Well Treated Patients Suffering From Depression And Experiencing Treatment-Emergent Sexual Dysfunction 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Results Of A New Study Of Brintellix® (vortioxetine) vs. Escitalopram On Sexual Functioning In Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction 6/17/2014
H. Lundbeck A/S (LUN.CO) Release: New Study Shows That Brintellix® (Vortioxetine) Improves Cognitive Performance And Function In Adult Patients With Major Depression 6/16/2014
Hemispherx Biopharma (HEB) Announces New Publication With Potential Insight Into High Mortality Rate In Middle Eastern Respiratory Syndrome (MERS) 6/16/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
Boehringer Ingelheim Corporation Release: Antidote For Rapid Reversal Of Pradaxa® (Dabigatran Etexilate) Progresses Into Next Stage Of Clinical Investigation With Study In Patients 5/22/2014
GlaxoSmithKline (GSK) Touts Positive Incruse™-Ellipta®-Advair®-Diskus® Combo Data 5/20/2014
Biohit Release: Enrollment To Clinical Trials For Prevention Of Migraine-Type Headache 5/19/2014
Biohit Starts Two Clinical Trials With Acetium® Capsule For Prevention Of Migraine-Type Headache 4/29/2014
Head-To-Head Study Reveals Novartis AG (NVS) Lung Drug Not Inferior To GlaxoSmithKline (GSK)'s Seretide 4/28/2014
Saga Continues: Roche (RHHBY)'s Tamiflu No Better Than Tylenol At "Fighting Flu" 4/14/2014
FDA Grants Breakthrough Status Designation To Novartis AG (NVS)' Meningitis B Vaccine 4/8/2014
H. Lundbeck A/S (LUN.CO) Release: Treatment With Once-Monthly Abilify Maintena® (Aripiprazole) Significantly Reduces Hospitalisation Rates For Patients With Schizophrenia Compared With Daily Oral Antipsychotics 4/7/2014
Roche (RHHBY)-Backed Study Finds Tamiflu Saved Lives In Flu Pandemic 3/19/2014
uniQure And Chiesi Farmaceutici SpA Announce Six Year Follow-up Data from Glybera® Treated Patients 3/17/2014
Janssen Pharmaceutica N.V. Release: New Data Show XEPLION® Significantly Delays Time To Relapse Compared To Treatment As Usual With Oral Antipsychotic Monotherapy 3/4/2014
Baxter International, Inc. (BAX) Presents Data At EAHAD From Long-Term Outcomes Registry Reinforcing Prophylaxis Treatment Experience With ADVATE 2/27/2014
Roche (RHHBY) May Share Avastin Brain Cancer Data Amid Conflicting Results 2/21/2014
Ranbaxy Laboratories (RANBAXY.BO) Workers Fudged Test Results: FDA 1/28/2014
Teva Pharmaceutical Industries Limited (TEVA) Release: Data Demonstrates Key Genes Respond Differently To COPAXONE® (glatiramer acetate injection) Versus A Purported Generic Glatiramer Acetate 1/13/2014
German Watchdog Deals Setback To Bayer AG (BAYN.DE) Eye Drug Eylea 1/6/2014
AstraZeneca PLC (AZN)'s Arimidex Halves Breast Cancer Risk, Study Finds 12/12/2013
Lundbeck Inc. (LUN.CO) Release: New Study Showed Improvement In Cognitive Performance In Adult Patients Treated With Brintellix® (Vortioxetine) For Acute Episodes Of Major Depression 12/11/2013
Zealand Pharma  (ZEAL.CO) Informs That New Data Presented At The World Diabetes Congress Support Flexibility In Timing Of Administration For Lyxumia® 12/5/2013
Janssen Pharmaceutica N.V. Unveils New Data On Xeplion® In Various Stages Of Schizophrenia 12/2/2013
Boehringer Ingelheim Corporation Release: Pradaxa® (Dabigatran Etexilate) 150mg Bid Continues To Be The Only Oral Anticoagulant Which Showed Superior Ischaemic Stroke Reduction Vs. Warfarin In Its Pivotal Study RE-LY® 11/25/2013
Boehringer Ingelheim Corporation Planning Two New Global Clinical Trials For Pradaxa® (Dabigatran Etexilate) In Expanded Patient Populations 11/19/2013
First Human Data Show Promise Of Boehringer Ingelheim Corporation’s Specific Antidote For Immediate, Complete And Sustained Reversal Of Pradaxa®-Induced Anticoagulation 11/18/2013
EU Agency Questions AstraZeneca PLC (AZN) Over Heart Drug Trial 11/8/2013
Ibuprofen No Good in Treating Colds or Sore Throats, University of Southampton Study 11/5/2013
Roche (RHHBY)'s Avastin Boosts Survival in Advanced Ovarian Cancer 10/23/2013
Novo Nordisk A/S (NVO) Study Shows Tresiba Efficacy for Diabetes 9/26/2013
Data Show Sanofi (France) (SAN.PA)'s Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially When Fasting Plasma Glucose Was Controlled 9/24/2013
Roche (RHHBY)'s Perjeta Works in Early-Stage Breast Cancer 9/11/2013
Boehringer Ingelheim GmbH's Respimat Inhaler Meets Safety Goal in Study 9/3/2013
FDA Probes Brain Infection in Patient on Novartis AG (NVS)'s MS Drug 9/3/2013
Novartis AG (NVS)'s Afinitor® Fails Phase 3 Liver Cancer Trial 8/8/2013
Orexo AB: First Patient Dosed in New Study on Long-Term Adherence to Treatment of Opioid Dependence With Zubsolv® 8/7/2013
Deja Vu: Second Probe Finds Manipulated Trial Data for Novartis AG (NVS) Drug 8/5/2013
Celgene International Sárl (CELG) Release: Study of REVLIMID® (lenalidomide) in Patients with High-Risk Asymptomatic Smoldering Multiple Myeloma Published in The New England Journal of Medicine 8/1/2013
European Medicines Agency Approves SmPC Change to Baxter International, Inc. (BAX)’s ADVATE to Include Information on PK-Guided Dosing Study 7/22/2013
Roche (RHHBY)'s Avastin as Good as Novartis AG (NVS)'s Lucentis for AMD 7/19/2013
Boehringer Ingelheim Corporation Release: Benefits of Pradaxa® Maintained in Difficult to Treat Patients With Atrial Fibrillation and Symptomatic Heart Failure 7/16/2013
Novartis AG (NVS) Drug Study Data Manipulated: Kyoto Prefectrual University of Medicine 7/16/2013
Baxter International, Inc. (BAX) Presents ADVATE Data on Prophylaxis Management and Efficacy for Hemophilia A Patients 7/8/2013
Boehringer Ingelheim Corporation Release: New Long-Term Data Reinforce Safety Profile of Pradaxa® for Stroke Prevention in AF 6/17/2013
Celgene International Sárl (CELG) Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients With Rare Form of Blood Disease 6/17/2013
Novo Nordisk A/S (NVO) Release: Victoza® (Liraglutide [rDNA Origin] Injection) Safety Profile Further Supported at Scientific Workshop on Pancreatitis, Diabetes and Pancreatic Cancer 6/14/2013
AbbVie (ABBV) Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination With HUMIRA™ (adalimumab) for Rheumatoid Arthritis 6/13/2013
Bristol-Myers Squibb Company (BMY)'s Orencia Matches Abbott Laboratories (ABT)' Humira in Arthritis Study 6/12/2013
Merck & Co., Inc. (MRK) Joins Novo Nordisk A/S (NVO) to Reassure Safety of Diabetes Drugs 6/12/2013
Sanofi (France) (SAN.PA) Steps Up Diabetes Drive as Rivals Raise the Stakes 6/10/2013
Eisai Company, Ltd. (ESALY.PK) Confirms Therapeutic Effects of Lenvatinib in Patients With Melanoma in Strategic Collaboration With Quintiles, Inc. (Q) to Develop Eisai Anticancer Compounds 6/10/2013
New Bird Flu Found to be Resistant to Roche (RHHBY)'s Tamiflu 5/30/2013
Boehringer Ingelheim Corporation Release: New European Survey Highlights Ischaemic Stroke Protection as Treatment Priority for Patients With Atrial Fibrillation 5/28/2013
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S (LUN.CO): Study Shows Effects of Treatment With ABILIFY MAINTENA#0153; (Aripiprazole) on Psychiatric Hospitalization Rates for Patients With Schizophrenia1 5/21/2013
"Love Hormone" Promises Safer Births After Pfizer Inc. (PFE) Flop 5/21/2013
Teva Pharmaceutical Industries Limited (TEVA) Parkinson's Treatment Meets Study Goals 3/20/2013
German Cost Regulator Rejects Bayer AG (BAY.F) and Regeneron Pharmaceuticals, Inc. (REGN) Eye Drug 3/20/2013
EU Expands Use of Roche (RHHBY)'s Pegasys in Chronic Hepatitis C 3/18/2013
Ferring Pharmaceuticals Data Suggest Lower Risk of Cardiovascular Events or Deaths in Prostate Cancer Patients Treated With Degarelix Compared to LHRH Agonists 3/18/2013
AbbVie (ABBV) Seeks to Block Release of Clinical Trial Data 3/11/2013
Serious Side Effects Seen With Failed Merck & Co., Inc. (MRK) Niacin Drug 3/11/2013
Roche (RHHBY)'s Rituxan Cures Rare Skin-Blistering Disease in Study 3/8/2013
National Institute for Clinical Excellence (NICE) U-Turn on Novartis AG (NVS)'s Xolair for Asthma 3/7/2013
Boehringer Ingelheim Corporation Release: New Findings From Two Studies Support Substantial Benefit of Pradaxa® for Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism 2/21/2013
Pfizer Inc. (PFE) Reports Positive Results in Studies of Toviaz, Pristiq, Chantix 1/24/2013
Novartis AG (NVS) Says Afinitor Reduces Tumors in Rare Genetic Disease 1/11/2013
Merck & Co., Inc. (MRK)'s Tredaptive is Under Review by European Medicines Agency After Failed Trial 12/26/2012
Immune Response BioPharma Files for Orphan Designation of REMUNE for Pediatric HIV/AIDS 12/13/2012
Novo Nordisk A/S (NVO) Bets on Turning Victoza Into Obesity Blockbuster 12/12/2012
Celgene International Sárl (CELG) Release: Analysis of Post-Progression Outcomes in MM-015 Study Presented at the 54th American Society of Hematology Annual Meeting 12/11/2012
Genentech (RHHBY)'s Perjeta Extends Life of Breast Cancer Patients by 34 Pct 12/11/2012
Celgene (CELG) Release: REVLIMID® and VIDAZA® Combination Therapy Achieves Nearly 30 Percent Complete Response in Untreated Elderly Patients With Acute Myeloid Leukemia 12/11/2012
Boehringer Ingelheim Corporation Release: Treatment With Pradaxa® Associated With Better Patient Outcomes After a Major Bleeding Event Compared to Warfarin 12/10/2012
GlaxoSmithKline (GSK): We Conducted Paxil Clinical Trial Program Appropriately 12/7/2012
AstraZeneca PLC (AZN) Release: Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX® (fulvestrant) Injection 500 mg Compared With 250 mg.1,2 12/5/2012
Eli Lilly and Company (LLY)'s ED Drug, Cialis, Shows Promise in Rare Muscle Disease 11/30/2012
Digoxin for Atrial Fibrillation Questioned After Deaths, Study Published in the European Heart Journal 11/28/2012
Novo Nordisk A/S (NVO) Says New Data Show Victoza Advantage 11/27/2012
Roche (RHHBY)'s Avastin Shows Mixed Results in Glioblastoma 11/23/2012
Gilead Sciences, Inc. (GILD)'s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients 11/15/2012
Gilead Sciences, Inc. (GILD)'s Once-Daily Single Tablet Regimen Stribild™ Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naive HIV Patients 11/15/2012
Boehringer Ingelheim Corporation Release: Recruitment Complete for Trajenta ® (linagliptin) Cardiovascular Outcome Study in Patients With Type 2 Diabetes 11/8/2012
Boehringer Ingelheim Corporation Release: RELY-ABLE®: Unprecedented Long-Term Data Support Safety Profile and Sustained Efficacy of Pradaxa® for Stroke Prevention in AF 11/8/2012
Boehringer Ingelheim Corporation Release: Safety and Efficacy of Pradaxa® (dabigatran etexilate) Reconfirmed in Clinical Setting for VTE Prevention After Total Knee or Hip Replacement 11/6/2012
Novartis AG (NVS) Drug Works to Treat Rare Cushing's Disease 11/6/2012
Boehringer Ingelheim GmbH Release: FDA and FDA Reaffirm Important Health Benefits and Safety of Pradaxa® (dabigatran etexilate) for Patients With Atrial Fibrillation 11/5/2012
GlaxoSmithKline (GSK), Roche (RHHBY) Drugs Help Treat Breast Cancer in Brain 11/2/2012
Wealth of Worldwide Evidence on Boehringer Ingelheim GmbH's Pradaxa® Including First Clinical Data on Long-Term Efficacy and Safety of a Novel Oral Anticoagulant to be Presented at American Heart Association Scientific Sessions 10/31/2012
Novartis AG (NVS) Cannibalizes Gleevec to Boost New Cancer Drug 10/29/2012
Sleep Tight: GlaxoSmithKline (GSK) Vaccine Not Linked To Narcolepsy 10/19/2012
Eisai Company, Ltd. (ESALY.PK)'s Epilepsy Drug Helps Obese Patients Lose Weight 10/17/2012
Sanofi (France) (SAN.PA)'s Genzyme Corporation (GENZ) Makes Progress With MS Drugs 10/15/2012
Novartis AG (NVS)'s Gilenya Cuts Early Relapse, Brain Loss in MS Patients 10/12/2012
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People With Relapsing Forms of MS 10/11/2012
Sanofi (France) (SAN.PA) Says Zaltrap Cancer Drug Study Positive 10/9/2012
Sanofi (France) (SAN.PA) Flags Positive Study on Lantus Insulin 10/5/2012
Cancer Trials Show One Year on Roche (RHHBY)'s Herceptin is Best 10/1/2012
Celgene (CELG)'s Abraxane is Talk of Cancer Meeting 10/1/2012
New Janssen Pharmaceutica N.V. Data Demonstrate STELARA® (ustekinumab) is Effective, Well-Tolerated and Improved Quality of Life in Patients With Moderate to Severe Plaque Psoriasis 9/28/2012
Boehringer Ingelheim GmbH Release: Asian Populations With Atrial Fibrillation (AF) Benefit From Better Stroke Prevention With Pradaxa® (dabigatran etexilate) Compared to Warfarin 9/12/2012
New Data Confirms Safety of Novartis AG (NVS)'s Eye Drug Lucentis 9/5/2012
Novartis AG (NVS) Smoker's Cough Treatment Beats GlaxoSmithKline (GSK)'s Advair in Trial 8/29/2012
Bayer AG (BAY.F) Says Blood Thinner Cuts Risk of Repeat Heart Attack 8/29/2012
The Medicines Company (MDCO) Release: Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin 8/28/2012
AstraZeneca PLC (AZN) Release: New European Society of Cardiology Guidelines Recommend BRILINTA (Ticagrelor) in Acute Coronary Syndromes Patients With ST-Elevation 8/28/2012
Daiichi Sankyo, Inc. (4568.t), Eli Lilly and Company (LLY) Say Heart Drug Effient Fails to Meet Goal in a Phase III Trial 8/27/2012
Boehringer Ingelheim Corporation Release: Cost Effectiveness and Clinical Efficacy of Pradaxa® (Dabigatran Etexilate) Versus Rivaroxaban Analysed 8/24/2012
Bionor Pharma ASA Release: Study of Vacc-4x Combined With Celgene (CELG)'s Revlimid® (lenalidomide) in HIV Patients With Impaired Immune System Approved to Begin 8/13/2012
Pfizer Inc. (PFE)'s Torisel Drug Fails in a Combination Study 8/13/2012
Roche (RHHBY) Says Avastin Slows Brain Cancer Tumor Growth 8/10/2012
Bristol-Myers Squibb Company (BMY) & AstraZeneca PLC (AZN) Release: Pooled Analysis Showed Onglyza® (saxagliptin) Provided Improvements in Key Measures of Blood Sugar Control in Adults With Type 2 Diabetes at High Risk for CV Disease 7/30/2012
Roche (RHHBY)'s Lucentis Works to Treat Vision Loss from Diabetes 7/25/2012
AstraZeneca PLC (AZN) Starts New Study of Heart Drug Versus Rival 7/18/2012
GlaxoSmithKline (GSK), Shionogi & Co., Ltd. Say HIV Drug Beats Gilead Sciences, Inc. (GILD) Atripla in Test 7/11/2012
Merck KGaA (MKGAF.PK) Says Erbitux Fails in Stomach Cancer Trial 7/6/2012
Orexo AB Takes Large Step Forward on the Road to Improve Treatment for People Dependent on Opioid Pain Killers 7/2/2012
Boehringer Ingelheim Corporation Release: No Significant Difference in the Risk of Acute Coronary Syndrome (including Myocardial Infarction) Seen With Pradaxa®(dabigatran etexilate) Compared to Enoxaparin for VTE Prevention After Orthopaedic Surgery 6/25/2012
Genentech (RHHBY) Says Perjeta Combination Increased Survival in Breast Cancer Patients 6/22/2012
FDA Staff Question Value of Sanofi (France) (SAN.PA) Blood Clot Drug 6/18/2012
Sanofi (France) (SAN.PA) Announces Results of ORIGIN, the World's Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes 6/15/2012
GlaxoSmithKline (GSK)'s Avandia and University of Nottingham's Actos are Linked to Vision Problems 6/13/2012
New Epidemiological Data Provide Additional Safety Evidence for Sanofi (France) (SAN.PA)'s Lantus(R) 6/12/2012
Alkermes plc (ALKS) Release: INVEGA® SUSTENNA® Three-Month Formulation of Paliperidone Palmitate Enters Phase 3 Clinical Program for Schizophrenia 6/12/2012
Sanofi (France) (SAN.PA)'s Lantus Shows No Cancer, Heart Risks: Study 6/12/2012
Novo Nordisk A/S (NVO) Says Victoza Superior to Amylin Pharmaceuticals, Inc. (AMLN) Rival 6/12/2012
Sanofi (France) (SAN.PA)'s Lantus Cut Blood Sugar More Than Merck & Co., Inc. (MRK)'s Januvia 6/11/2012
Data From Follow-Up Study of Vertex Pharmaceuticals Incorporated (VRTX)' KALYDECO™ (ivacaftor) Showed Durable Improvements in Lung Function and Other Measures of Disease in People With Cystic Fibrosis Who Have a Specific Genetic Mutation (G551D) 6/8/2012
Roche (RHHBY)'s Actemra Beats Abbott Laboratories (ABT) Drug in RA Trial 6/7/2012
European Medicines Evaluation Agency Confirms Boehringer Ingelheim Corporation's Pradaxa Benefits, But Wants Clearer Guidance 5/25/2012
Roche (RHHBY)'s Genentech (RHHBY) to Take Part in First-ever Alzheimer's Prevention Trial 5/21/2012
Merck KGaA (MKGAF.PK)'s Erbitux Fails in Colon Cancer Study 5/9/2012
Roche (RHHBY)'s Avastin and Novartis AG (NVS)'s Lucentis Equal for Treating Wet AMD - National Institutes of Health (NIH) Study 5/2/2012
New Tysabri Data Presented at 64th Annual American Academy of Neurology Meeting Highlight Biogen Idec, Inc. (Massachusetts) (BIIB) & Biogen Idec, Inc. (Massachusetts) (BIIB) Commitment to Improving Outcomes in Multiple Sclerosis 4/27/2012
Johnson & Johnson (JNJ) Alzheimer's Med Cut Chemical Tied to Brain Tangles 4/3/2012
Servier's Protelos Effective Against Weak Bones 3/26/2012
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Complete Registrational Program for Relovair; Reports Topline Results From Relovair(TM) vs. Advair(R) Phase III Studies in COPD 3/23/2012
OncoGenex Pharmaceuticals Inc. Doubles Down on Prostate Cancer, as Competition Heats Up 3/12/2012
Novartis AG (NVS) Cancer Drugs Fight Deadly Ebola Virus in Lab, Researchers Find 3/2/2012
Roche (RHHBY)'s Zelboraf May Double Survival for Some Melanoma Patients 2/24/2012
FDA Grants Orphan Drug Status for CF102 for the Treatment of Hepatocellular Carcinoma to Can-Fite BioPharma 2/23/2012
European Medicines Evaluation Agency Recommends Lifting Suspension of Bayer HealthCare (BAY)'s Trasylol 2/21/2012
AB Science (AB.PA) Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival as Compared to Pfizer Inc. (PFE)'s Sutent®in Gleevec®-resistant GIST 2/1/2012
Alkermes plc (ALKS) Initiates Open-Label Pilot Study of VIVITROL® to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence 1/31/2012
Allos Therapeutics, Inc. (ALTH) Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at theEuropean Medicines Evaluation Agency 1/30/2012
Roche (RHHBY)'s Avastin Fights Early Breast Cancer in 2 Studies: Will it be Re-approved? 1/27/2012
GlaxoSmithKline (GSK)'s Dutasteride May Slow Low-Risk Prostate Cancer: Debate Heats Up 1/24/2012
Roche (RHHBY) Melanoma Drug Spurs Growth of Other Skin Cancers: Study 1/20/2012
Sapheon, Inc. Announces One Year First-In-Man Data; Enrollment Commences in European Post Market Study 1/19/2012
Teva Pharmaceutical Industries Limited (TEVA) Release: Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair in Multiple Sclerosis Patients Treated with COPAXONE® 1/3/2012
Roche (RHHBY)'s Avastin Disappoints Against Ovarian Cancer 1/3/2012
Study Challenges Bristol-Myers Squibb Company (BMY) on Bristol-Myers Squibb Company (BMY) and Sanofi (France) (SAN.PA)'s Plavix 12/29/2011
EarlySense Release: Studies Show that EarlySense’s Contact-Free Patient Monitoring System Effectively Helps Hospital Patients Avoid Pressure Ulcers 12/19/2011
Clinuvel Announces Positive Results From Pivotal European Phase III Study: Endpoints Demonstrate Clinically Relevant Treatment Effect of Afamelanotide 12/19/2011
Human Genome Sciences, Inc. (HGSI) and GlaxoSmithKline (GSK) Initiate Phase 3 Trial of Belimumab (BENLYSTA®) Administered Subcutaneously in Subjects with Systemic Lupus Erythematosus 12/15/2011
Celgene International Sárl (CELG) Release: Final Phase II Data Evaluating REVLIMID® and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia 12/14/2011
Celgene International Sárl (CELG) Release: Premiere Cooperative Group in Adult Lymphoma Research (GELA) Chooses REVLIMID® for Study in Second Most Common Lymphoma Subtype 12/14/2011
Celgene International Sárl (CELG) Release: Phase III Study Evaluating REVLIMID® in Patients with High-Risk Smoldering Multiple Myeloma Presented at American Society of Hematology 12/14/2011
Two Novartis AG (NVS) Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 12/13/2011
Celgene International Sárl (CELG) Release: Final Data from Phase II Multi-Center Study Evaluating Combination of VIDAZA® and REVLIMID® in Higher-Risk MDS Patients Presented at American Society of Hematology 12/13/2011
Celgene International Sárl (CELG) Release: REVLIMID® Evaluated in Combination with Rituximab as a Potential Treatment for Patients with Treatment-Naive Chronic Lymphocytic Leukemia 12/13/2011
Celgene International Sárl (CELG) Release: Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic Lymphocytic Leukemia 12/12/2011
Celgene International Sárl (CELG) Release: Results from a Comparative Analysis Shows REVLIMID® Demonstrates Statistically Significant Reduction in Risk of Death and No Evidence of Increased Risk of Progression to AML in Patients with Deletion 5q MDS Compared with Best Supportive Care 12/12/2011
Roche (RHHBY) Absorbs New Setback for Avastin as Cancer Treatment 12/12/2011
Latest Data on Novartis AG (NVS) Afinitor Confirms Efficacy 12/9/2011
GlaxoSmithKline (GSK) Drug Fails to Hit Goal in Breast Cancer Trial 12/9/2011
Boehringer Ingelheim Corporation,Eli Lilly and Company (LLY) Release: Linagliptin Demonstrates Meaningful Improvement in Glycaemic Control in Initial Combination Therapy with Metformin 12/8/2011
Pooled Analysis: Fewer Major Adverse Cardiovascular Events in People with Type 2 Diabetes Treated with Merck Sharp & Dohme (MRK)'s JANUVIA ® (sitagliptin) 12/6/2011
Novo Nordisk A/S (NVO) Release: Data Show That the Combination of Insulin Degludec/Insulin Aspart Significantly Reduced Hypoglycaemia in Type 1 and Type 2 Diabetes Patients 12/6/2011
Regeneron Pharmaceuticals, Inc. (REGN)-Bayer HealthCare (BAY) Drug Matches Lucentis at 2 Years in Fewer Doses 12/6/2011
Midatech Group Receives Regulatory Approval for Clinically Testing Ultra-small Gold Nanoparticles 11/15/2011
Sanofi (France) (SASY.PA)'s Multaq Doubled Deaths from Heart Disease in Study 11/15/2011
The Medicines Company (MDCO) Release: German Researchers Reaffirm Utility of Angiomax(R)/Angiox(R) (Bivalirudin) in High Risk PCI Patients 11/14/2011
Alkermes plc (ALKS) Release: New Long-Term Data on VIVITROL® Showed Sustained Efficacy and Safety over 18 Months of Treatment 11/9/2011
Studies Show GlaxoSmithKline (GSK)'s HPV Vaccine Fights Cervical Cancer 11/9/2011
Boehringer Ingelheim Corporation Release: Hepatitis C: Interferon-free Combination of BI 201335 Plus BI 207127 and ribavirin Shows up to 76% of Patients Achieve a Virological Response at Week 12, and 59% Achieve SVR12 with 16 Weeks Treatment 1 11/7/2011
Ticagrelor Does Not Affect Pulmonary Function in ACS Patients, University of Sheffield Study 10/14/2011
Novartis AG (NVS)' Onbrez Beats Boehringer Ingelheim Corporation/Pfizer Inc. (PFE)'s Spiriva for COPD Quality of Life 10/4/2011
Merck & Co., Inc. (MRK), Sanofi (France) (SASY.PA) Cancer Vaccine Beats GlaxoSmithKline (GSK)'s Rival on Cost 9/29/2011
Amylin Pharmaceuticals, Inc. (AMLN) Release: Analyses Find Type 2 Diabetes Patients Treated with BYDUREON(TM) Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 9/12/2011
National Institute for Clinical Excellence (NICE) Questions Merck & Co., Inc. (MRK), Nycomed COPD Drug 9/12/2011
AstraZeneca PLC (AZN)'s Crestor Fails to Beat Pfizer Inc. (PFE)'s Lipitor 9/6/2011
Head-to-Head Data on AstraZeneca PLC (AZN)'s Crestor Vs. Pfizer Inc. (PFE)'s Lipitor Results Due Soon 8/31/2011
AstraZeneca PLC (AZN) Bloodthinner Shows Mortality Benefit Versus Sanofi (France) (SASY.PA)'s Plavix 8/30/2011
GlaxoSmithKline (GSK) HPV Vaccine Protects Women From Anal Cancer 8/24/2011
Roche (RHHBY)'s Herceptin Has Higher Heart Risk for Older Women 8/10/2011
Roche (RHHBY) Cancer Drug Rejected by National Institute for Clinical Excellence (NICE) Found to Triple Survival Time 7/26/2011
Bayer AG (BAY.F)'s Xarelto Blood Thinner Matched Warfarin in Japanese Safety Study 7/25/2011
Sanofi (France) (SASY.PA) Halts Clinical Trial of Heart Drug Multaq 7/7/2011
AstraZeneca PLC (AZN)'s Brilinta Worse With High-Dose Aspirin in Analysis 6/29/2011



//-->